Aerovate

About Aerovate

Aerovate Therapeutics operates as a clinical-stage biopharmaceutical firm with a dedicated focus on creating treatments for rare cardiopulmonary diseases. The company was incorporated in Delaware on December 21, 2018. Its primary asset is AV-101, an aerosolized, dry powder formulation of the drug imatinib, designed for the treatment of pulmonary arterial hypertension (PAH). This product aims to deliver the anti-proliferative effects of imatinib directly to the diseased blood vessels in the lungs, potentially offering a safer and more effective treatment compared to the oral version of the drug, which had previously shown efficacy but was hindered by systemic adverse events.

The company's strategy hinges on the targeted delivery of AV-101, which seeks to concentrate the therapeutic agent in the lungs while minimizing exposure to the rest of the body. Aerovate has successfully completed its Phase 1 clinical trial and is currently conducting the Phase 2b portion of its IMPAHCT Phase 2b/Phase 3 trial for AV-101 in adults with PAH. The business model is typical for a clinical-stage biopharmaceutical company, where value is built by advancing a drug candidate through the rigorous and costly phases of clinical trials, with the ultimate goal of obtaining regulatory approval and commercializing the product. Revenue generation is contingent upon the successful development, approval, and subsequent sale or licensing of AV-101.

Aerovate secured significant financial backing to fund its clinical development. In June 2021, the company completed its initial public offering (IPO), raising approximately $121.6 million in gross proceeds. This followed a successful $75 million Series A financing round in 2020, which was co-led by an undisclosed investor and Sofinnova Investments. The company's leadership team, including CEO Timothy Noyes, possesses extensive experience in developing and commercializing therapies for rare diseases, particularly in the pulmonary space.